Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Curebase
United States
- San Francisco, CA
- 05/05/2022
- Series B
- $40,000,000
At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We offer the full package of robust services and tools built in-house to run clinical studies end-to-end that reach more patients through in-home, community-based, and site-based care, leading to faster, cost effective, and diverse studies.
We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.
- Industry Research Services
- Website https://www.curebase.com/
- LinkedIn https://www.linkedin.com/company/curebase/
Related People
Tom LembergFounder
United States -
San Francisco, California
Founder & CEO at Curebase.
Curebase is a decentralized clinical trials software platform and clinical service provider. We enable any patient, anywhere to participate in clinical trials at home and with their own doctor.
Our mission is to accelerate the clinical trial process by 50%, increase patient diversity by 50%, and transform the $50B+ clinical trial market.
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)